‘The Group Room’ Radio Talk Show Celebrates Three Years on the Air

Publication
Article
Oncology NEWS InternationalOncology NEWS International Vol 8 No 4
Volume 8
Issue 4

LOS ANGELES-“The Group Room,” a nationally syndicated cancer radio talk show, entered its third year on the air with new markets, accolades for its host Selma Schimmel, and a new book based on the show.

LOS ANGELES—“The Group Room,” a nationally syndicated cancer radio talk show, entered its third year on the air with new markets, accolades for its host Selma Schimmel, and a new book based on the show.

The recently signed new markets are in Alabama, Florida, Idaho, Pennsylvania, and Tennessee. The book is called Cancer Talk, and the honor for Ms. Schimmel is being named one of the “Heavy Hundred” by the radio industry publication Talkers Magazine. The “Heavy Hundred” represent the most important radio talk show hosts in America. Ms. Schimmel is a 16-year breast cancer survivor and founder of Vital Options, the national cancer support, advocacy, and communications organization.

“It is an honor to receive this recognition, especially when you consider that there are 4,500 talk shows nationwide,” Ms. Schimmel said. “I want to acknowledge Premiere Radio Networks and our founding sponsor, Bristol-Myers Squibb; corporate sponsors Ortho Biotech and Pharmacia & Upjohn; and the hundreds of local supporters and radio stations who make this show possible every week.”

The program airs live each Sunday from 4 to 6 pm Eastern Daylight Time in major markets and can also be heard live on the Internet at www.vitaloptions.org.

Cancer Talk, a book of hope and lessons in endurance culled from conversations on the radio show, was written by Ms. Schimmel and is due out this spring from Broadway Books, a division of Random House.

Recent Videos
“It’s a drug that I’m very comfortable with, and it is a drug I’ll likely use primarily in the first-line setting,” stated Jorge Nieva, MD, on taletrectinib in non–small cell lung cancer.
4 experts in this video
4 experts in this video
Those being treated for peritoneal carcinomatosis may not have to experience the complication rates or prolonged recovery associated with surgical options.
For patients with peritoneal carcinomatosis, integrating PIPAC into a treatment regimen does not interrupt their systemic therapy.